Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even worsen survival. Only allogeneic transplantation may have curative potential in some patients. However, the high non-relapse mortality and incidence of chronic graft-versus-host disease have raised controversy regarding this procedure. In this review, we will address the role of upfront and delayed allogeneic transplant. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Download PDF
18 pages

Loading next page...
 
/lp/springer-journals/current-role-of-allogeneic-stem-cell-transplantation-in-multiple-PjLuBm3nmN
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-022-00195-3
Publisher site
See Article on Publisher Site

Abstract

Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even worsen survival. Only allogeneic transplantation may have curative potential in some patients. However, the high non-relapse mortality and incidence of chronic graft-versus-host disease have raised controversy regarding this procedure. In this review, we will address the role of upfront and delayed allogeneic transplant.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 1, 2022

Keywords: Multiple myeloma; Allogeneic transplantation; Chronic graft-versus-host disease; CAR-T cell therapy

References

  • Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
    Gay, F; Oliva, S; Petrucci, MT
  • Autologous transplantation and maintenance therapy in multiple myeloma
    Palumbo, A; Cavallo, F; Gay, F
  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
    Cavo, M; Gay, F; Beksac, M
  • Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
    Rajkumar, SV
  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
    de Larrea, CF; Kyle, RA; Durie, BG
  • Interpretation of cytogenetic results in multiple myeloma for clinical practice
    Rajan, AM; Rajkumar, SV
  • Revised international staging system for multiple myeloma: a report from international Myeloma Working Group
    Palumbo, A; Avet-Loiseau, H; Oliva, S
  • Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy
    Thomas, ED; Lochte, HL; Lu, WC; Ferrebee, JW
  • Bone marrow transplantation in three patients with multiple myeloma
    Gahrton, G; Ringdén, O; Lönnqvist, B; Lindquist, R; Ljungman, P
  • Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation
    Gahrton, G; Tura, S; Ljungman, P
  • The cost of hematopoietic stem-cell transplantation in the United States
    Broder, MS; Quock, TP; Chang, E
  • Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
    Rajkumar, SV; Harousseau, JL
  • Value and cost of myeloma therapy
    Rajkumar, SV
  • Comparison of outcomes of allogeneic hematopoietic cell transplantation for multiple myeloma using three different conditioning regimens
    Maymani, H; Lin, P; Saliba, RM
  • Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
    Crawley, C; Iacobelli, S; Björkstrand, B; Apperley, JF; Niederwieser, D; Gahrton, G
  • When to recommend allogeneic transplant in multiple myeloma
    Gertz, MA
  • Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome
    Bensinger, WI; Buckner, CD; Anasetti, C
  • Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
    Gahrton, G; Tura, S; Ljungman, P
  • Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation
    Bjorkstrand, BB; Ljungman, P; Svensson, H
  • Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres
    Gahrton, G; Svensson, H; Cavo, M
  • Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991–2012) on behalf of EBMT CMWP
    Hayden, PJ; Iacobelli, S; Pérez-Simón, JA
  • Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma
    Kroger, N; Einsele, H; Derigs, G; Wandt, H; Krull, A; Zander, A
  • Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    McSweeney, PA; Niederwieser, D; Shizuru, JA
  • Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
    Garban, F; Attal, M; Michallet, M
  • A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
    Rosiñol, L; Pérez-Simón, JA; Sureda, A
  • A comparison of allografting with autografting for newly diagnosed myeloma
    Bruno, B; Rotta, M; Patriarca, F
  • Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
    Giaccone, L; Storer, B; Patriarca, F
  • Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up
    Björkstrand, B; Iacobelli, S; Hegenbart, U
  • Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
    Gahrton, G; Iacobelli, S; Björkstrand, B
  • Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
    Krishnan, A; Pasquini, MC; Logan, B
  • Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial
    Giralt, S; Costa, LJ; Maloney, D
  • Post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis in multiple myeloma patients who underwent allogeneic hematopoietic cell transplantation: first comparison by donor type. A Study from the chronic malignancies working party of the European society for blood and marrow transplantation
    Sahebi, F; Eikema, DJ; Koster, L
  • Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model
    Ploemacher, RE; Johnson, KW; Rombouts, EJ
  • Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies
    Nemecek, ER; Guthrie, KA; Sorror, ML
  • Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation—a large retrospective study by the Chronic Malignancies Working Party of the EBMT
    Gran, C; Wang, J; Nahi, H
  • Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
    Costa, LJ; Iacobelli, S; Pasquini, MC
  • Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
    Knop, S; Engelhardt, M; Liebisch, P
  • Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
    Schneidawind, C; Duerr-Stoerzer, S; Faul, C
  • Long-term follow-up of a donor versus no-donor comparison in patients with multiple myeloma in first relapse after failing autologous transplantation
    Patriarca, F; Bruno, B; Einsele, H
  • Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
    Greil, C; Engelhardt, M; Ihorst, G
  • Presalvage international staging system stage and other important outcome associations in CD34(+)-selected allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Bryant, AR; Hilden, P; Giralt, S
  • B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
    Carpenter, RO; Evbuomwan, MO; Pittaluga, S
  • Idecabtagene vicleucel in relapsed and refractory multiple myeloma
    Munshi, NC; Anderson, LD; Shah, N
  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
    Berdeja, JG; Madduri, D; Usmani, SZ
  • Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)
    Mailankody, S; Jakubowiak, AJ; Htut, M
  • Results from lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
    Kumar, SK; Baz, RC; Orlowski, RZ
  • Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Mailankody, S; Liedtke, M; Sidana, S
  • Successful treatment of relapsed/refractory extramedullary multiple myeloma with anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation: a case report and a review of the contemporary literature
    Qian, Y; Qian, Z; Zhao, X
  • HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Luznik, L; O'Donnell, PV; Symons, HJ
  • Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis
    Castagna, L; Mussetti, A; Devillier, R
  • Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: an EBMT/CIBMTR report
    Sahebi, F; Garderet, L; Kanate, AS
  • Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
    Paviglianiti, A; Xavier, E; Ruggeri, A
  • Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
    Bethge, WA; Eyrich, M; Mielke, S
  • Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma
    Green, DJ; Maloney, DG; Storer, BE
  • Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study
    LeBlanc, R; Ahmad, I; Terra, R
  • Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
    Vincent, L; Gras, L; Ceballos, P
  • Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation
    Alsina, M; Becker, PS; Zhong, X
  • Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    Kneppers, E; van der Holt, B; Kersten, MJ
  • Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients
    Montefusco, V; Mussetti, A; Rezzonico, F
  • Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
    Kröger, N; Zabelina, T; Klyuchnikov, E
  • Allogeneic transplantation in multiple myeloma-does it still have a place?
    Gahrton, G; Iacobelli, S; Garderet, L; Yakoub-Agha, I; Schönland, S
  • Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
    Lokhorst, HM; van der Holt, B; Cornelissen, JJ
  • Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only
    LeBlanc, R; Claveau, JS; Ahmad, I
  • Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
    Caballero-Velázquez, T; Calderón-Cabrera, C; López-Corral, L
  • Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
    Raje, NS; Anaissie, E; Kumar, SK
  • Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation
    Marty, FM; Ljungman, P; Chemaly, RF
  • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective
    Tomblyn, M; Chiller, T; Einsele, H
  • Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
    Majhail, NS; Rizzo, JD; Lee, SJ
  • The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation
    Farina, L; Bruno, B; Patriarca, F
  • Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma
    Saad, A; Mahindra, A; Zhang, MJ
  • Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
    Sorror, ML; Maris, MB; Storb, R
  • Validation of the hematopoietic cell transplantation-specific comorbidity index in nonmyeloablative allogeneic stem cell transplantation
    Veeraputhiran, M; Yang, L; Sundaram, V
  • Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study
    Maziarz, RT; Brazauskas, R; Chen, M
  • Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
    Engelhardt, M; Ihorst, G; Duque-Afonso, J
  • Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients
    Barba, P; Piñana, JL; Fernández-Avilés, F
  • Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation
    Parimon, T; Madtes, DK; Au, DH; Clark, JG; Chien, JW
  • Impact of pretransplantation renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation
    Farhadfar, N; Dias, A; Wang, T
  • International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    Giralt, S; Stadtmauer, EA; Harousseau, JL
  • Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
    Gonsalves, WI; Buadi, FK; Ailawadhi, S
  • Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival
    Lokhorst, HM; van der Holt, B; Cornelissen, JJ
  • Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
    de Lavallade, H; El-Cheikh, J; Faucher, C
  • Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability
    Patriarca, F; Einsele, H; Spina, F
  • Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation
    Auner, HW; Szydlo, R; van Biezen, A
  • Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation
    Freytes, CO; Vesole, DH; LeRademacher, J
  • Reducing treatment-related mortality did not improve outcomes of allogeneic myeloablative hematopoietic cell transplantation for high-risk multiple myeloma: a university of michigan prospective series
    Pawarode, A; Mineishi, S; Reddy, P
  • Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
    Sobh, M; Michallet, M; Dubois, V
  • Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma
    Shingaki, S; Tsukada, N; Ishida, T; Suzuki, K
  • The role of allogeneic transplantation for multiple myeloma in the era of novel agents: a study from the Japanese Society of Myeloma
    Kawamura, K; Tsukada, N; Kanda, Y
  • Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors
    Van Elssen, C; van Gorkom, G; Voorter, C